- Specializing in Creating Customized IVRs, Voice, SMS, Chat and HIPAA Compliant Secure Message Applications
Specializing in Creating Customized IVRs, Voice, SMS, Chat and HIPAA Compliant Secure Message Applications
Category: Clinical Trials
Clinical trial recruitment that earns patient trust
Clinical trial recruitment is often thought of as a marketing problem, but at its core it is an operational one. Each potential participant has a different history, different constraints, and a personal timeline; solving recruitment in rare-disease studies means designing communications and intake workflows that earn trust and reduce friction.
Clinical trial retention: communications operations that matter
Clinical trial retention and late-stage data integrity are operational problems, not marketing problems. When a Phase 3 study crosses the enrollment finish line, the work shifts from finding participants to keeping them engaged and collecting high-quality patient-reported outcomes (PRO).
Clinical trial enrollment: what to plan for when sites can’t enroll
Clinical trial recruitment is as much an operational problem as it is a scientific one. Trials can be derailed not by the protocol but by timing: an outbreak near a site, expiring supplies, or a sudden change in local vaccine policy can all compress the window for safe enrollment.
AI in clinical trials: practical questions for operations
Putting AI in clinical trials is not just a technology shift. It is an operational one. Embedding AI promises faster patient recruitment, smarter site selection, and earlier detection of data issues. What operations leaders need to worry about is how those AI-driven recommendations change day-to-day workflows, where responsibility lands, and whether the new flows increase patient burden.
Clinical trial workflows that hold up under interim scrutiny
Clinical trial workflows are fundamentally a per-person scheduling problem. Each participant has their own baseline visit, dosing day, and follow-up window, and those individual timelines drive when you must collect patient-reported outcome (PRO) data, run blinded biomarker checks, and perform safety follow-ups. When an interim readout looms, the operational work of making sure every participant was contacted, every PRO was recorded, and every safety flag was triaged becomes urgent, not theoretical. As sponsors plan for blinded interim analyses months or years out, these operational tasks are calendar-driven and predictable if you plan for them.
When clinical trial recruitment lists don’t convert: fixing the handoff
Clinical trial recruitment is often talked about as a sourcing problem. The stubborn operational failure actually lives in the handoff between identification and enrollment. Recent reporting that a sponsor’s investment in an ambient-AI tool produced an enormous list of flagged patients is a reminder: a machine can point at potential matches, but it cannot make a site ready to screen, consent, and randomize them.
Clinical trial recruitment stalls where pre-screening and follow-up lag
Why enrollment funnels leak and what sponsors and sites should ask about participant identification, screening capacity, and retention Clinical trial recruitment is an operational problem before it is a marketing problem. When enrollment lags, the root causes are usually process gaps: participant identification that does not scale, pre-screening capacity that is chronically underfunded, and follow-up workflows that do not match participants’ lives. A recent analysis from the USC Schaeffer Institute on Alzheimer’s disease trial recruitment highlights four high-leverage areas: protocol design and site selection, participant identification, funding of pre-screening, and long-term recruitment infrastructure. These are systemic issues. Below we translate
Clinical trial recruitment: operational workflows that scale
Why per-participant timelines, intake outreach, and voice-first engagement matter for enrollment and retention Clinical trial recruitment is not a marketing problem. It is an operations problem where each potential participant has a unique timeline, needs a clear consent path, and often responds on the channels they already use. A hospital in Plymouth recently made news for substantially increasing trial enrollment, and the operational details matter: site-level choices about how patients are approached, how samples are handled, and how follow-up is scheduled can change outcomes as much as outreach budgets do. The practical question for sponsors, site research offices, and contract
When trial enrollment windows compress: what breaks first in recruitment operations
Faster timelines expose bottlenecks in screening, consent, and per-participant follow-up that sponsors and CROs need to address Clinical trial recruitment is an operational problem as much as a scientific one. When enrollment windows shorten, the usual manual tactics stop working: sites get overwhelmed, screening funnels clog, and participant follow-up slips. Recent reporting that some global competitors are completing trials in half the time is a reminder that sponsors and contract research organizations (CROs) need to revisit how they run recruitment and ongoing participant communications. The core question is simple: can your recruitment and engagement systems keep up with each participant’s